|
Accession number;06A0654483
|
| Title;Review/Advances in Neurological Therapeutics (2005). Multiple Sclerosis. |
| Author;
OSOEGAWA MANABU
(Kyushu Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.369-372(2006)
|
| Figure&Table&Reference;REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Multiple sclerosis (MS) is the prototypic inflammatory demyelinating disorder of the central nervous system (CNS). The medical treatment of MS consists primarily of corticosteroid therapy to enhance recovery from relapse and pharmaceutic intervention to help manage symptoms. In recent years disease-modifying drug in the treatment of MS have been developed, including IFN.BETA., glatiramer acetate, mitoxantorone and natalizumab. These drugs have been reported to reduce annual relapse rates, clinical disability scale and disease activity on MRI. The Efficacy and safety of Interferon.BETA. and glatiramer acetate treatment in MS patients have already been demonstrated during longterm follow up of patients, Mitoxantrone is an effective and generally tolerated disease-modifying treatment for patients with worsening relapsing-remitting and secondary progressive MS but its major limitation is its potential for cardiotoxicity due to cumulative dose. Natalizumab is the first in its classes of agents called selective adhesion molecule inhibitors, which have showed promising results in the treatment of MS; however the long-term safety of natalizumab has yet to be established. This article focuses on the advancements in the treatment of MS in the year 2005. (author abst.) |
|
|
|
Related Articles;
|
